PHAXIAM Therapeutics S.A. Operating Expense
PHAXIAM Therapeutics S.A. reported Operating Expense of EUR 12.68 million for the 6-month period ending 2023-06-30, per its 6-K filed 2023-09-26.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:OperatingExpense · last filed 2023-09-26
| Period end | Operating Expense 6 month | Operating Expense 12 month |
|---|---|---|
| 2023-06-30 | 12.68M EUR 6-K · filed 2023-09-26 | |
| 2022-12-31 | 33.79M EUR 20-F · filed 2023-03-28 | |
| 2022-06-30 | 25.21M EUR 6-K · filed 2023-09-26 | |
| 2021-12-31 | 60.70M EUR 20-F · filed 2023-03-28 | |
| 2021-06-30 | 31.24M EUR 6-K · filed 2022-09-12 | |
| 2020-12-31 | 72.55M EUR 20-F · filed 2023-03-28 | |
| 2020-06-30 | 37.22M EUR 6-K · filed 2021-09-20 | |
| 2019-12-31 | 69.36M EUR 20-F · filed 2022-04-27 | |
| 2019-06-30 | 33.21M EUR 6-K · filed 2020-09-21 | |
| 2018-12-31 | 48.07M EUR 20-F · filed 2021-03-08 | |
| 2018-06-30 | 24.14M EUR 6-K · filed 2019-09-26 | |
| 2017-12-31 | 34.25M EUR 20-F · filed 2020-03-18 | |
| 2016-12-31 | 26.53M EUR 20-F · filed 2019-03-29 | |
| 2015-12-31 | 18.51M EUR 20-F/A · filed 2018-05-23 |